CollPlant Biotechnologies's quarterly market cap
declined
from Sep. 2025 ($34.37 Mil) to Dec. 2025 ($17.92 Mil) and
declined
from Dec. 2025 ($17.92 Mil) to Mar. 2026 ($7.73 Mil).
CollPlant Biotechnologies's annual market cap
declined
from Dec. 2023 ($73.18 Mil) to Dec. 2024 ($41.24 Mil) and
declined
from Dec. 2024 ($41.24 Mil) to Dec. 2025 ($17.92 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CollPlant Biotechnologies's Enterprise Value for Today is $3.30 Mil.
CollPlant Biotechnologies (NAS:CLGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CollPlant Biotechnologies Market Cap Related Terms
CollPlant Biotechnologies Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CollPlant Biotechnologies's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Market Cap distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CollPlant Biotechnologies (CLGN) has a Market Cap of $4.91 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CollPlant Biotechnologies and its competitors. According to the industry distribution chart, CollPlant Biotechnologies ranks #1303 out of 1427 companies in the Biotechnology industry, placing it in the top 91.3%.
Is CollPlant Biotechnologies' Market Cap too high?
CollPlant Biotechnologies' current Market Cap is $4.91 Mil. The Biotechnology industry median Market Cap is 119.57. CollPlant Biotechnologies' value of $4.91 Mil is 95.9% below this industry median. Based on the distribution chart, CollPlant Biotechnologies ranks #1303 out of 1427 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Market Cap compare to CPMV and TCRT?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #1303 out of 1427 companies for Market Cap. This places CollPlant Biotechnologies in the lower half of its industry. The industry median Market Cap is 119.57. CollPlant Biotechnologies' value of $4.91 Mil is 95.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CollPlant Biotechnologies's current Market Cap of $4.91 Mil is 95.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current Market Cap is $4.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.34 — trading 17.3% above its estimated fair value. The current Market Cap is $4.91 Mil and 95.9% below the Biotechnology industry median of 119.57. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current Market Cap is $4.91 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of $0.34 is trading 17.3% above its estimated GF Value™ of $0.29.
GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.
Key valuation signals for CLGN:
Market Cap: $4.91 Mil
GF Value™: $0.29 vs. price of $0.34 (17.3% above fair value)
Industry Position: 95.9% below the Biotechnology median (#1303 of 1427)
No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score
Get the complete analysis for CLGN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLGN has been successfully added to your 
